May 17, 2020

The role of pharma packaging innovation in tackling antibiotic resistance

Supply Chain
Digital health
Rich Quelch, Global Head of Ma...
6 min
 antibiotic resistance
Antimicrobial resistance (AMR) is a complex and global issue, affecting all regions of the world. If current trends continue, it’s believed by 2050 an...

Antimicrobial resistance (AMR) is a complex and global issue, affecting all regions of the world. If current trends continue, it’s believed by 2050 antibiotic resistance will cause more deaths per year than cancer, becoming the world’s biggest killer.

As such, AMR is currently high on the political agenda of nation’s around the world as a sustainable solution is sought to reduce the rate at which antimicrobial pathogens are developing immunity to modern medicine.

However, the role of pharma packaging innovation is rarely discussed. While packaging alone does not hold the answer, it has an important part to play in making sure the healthcare system is part of the solution and not the problem.

Understanding the problem

To have a meaningful debate on the AMR crisis, it’s firstly important to understand the key factors currently contributing to its development.

The following contributors are widely cited as accelerating the rate at which bacteria is becoming immune and the emergence of more resistant strains: pharmaceutical waste; the over-prescribing and lack of access to antibiotic drugs; falsification of medicines; poor hygiene practices and the increase in global trade and travel.

The consequences of AMR are far-reaching, reducing our ability to treat common infectious diseases resulting in prolonged illness, more complications and higher fatality rates; the accelerated spread of infections due to ineffective treatments; compromising advances in medicines because of the risk of infection; and placing increasing financial pressure on global health care systems.

Since the historic United Nations Declaration on AMR was agreed in 2016, efforts have intensified across scientific, political and economic spheres to tackle it. However, evidence suggests while positive steps have been taken to slow the pace of AMR, there’s still a long way to go.

The World Health Organization (WHO) released a progress report in the summer which summarised: “progress with developing and implementing plans is greater in high-income than low-income countries but all countries have scope for improvement. No country is reporting established sustained capacity at scale in all domains”.

If this was a school report it would be “showing promise but must do better”.

Strengthening the frontline

Overuse and incorrect use of antibiotics is a major driver of resistance. A recent UK study estimated a fifth of prescriptions are inappropriately prescribed by GPs for illnesses such as a sore throat, cough, sinusitis and ear infections.

There’s a growing body of evidence suggesting the mismatch between dose amounts and course-length mandated by drug manufacturers and prescribers is leading to a considerable quantity of wasted and redundant antibiotics.

For example, a study published in the Australian and New Zealand Journal of Public Health found out of 32 of the most common antibiotic-prescribing scenarios, 10 had surplus doses left over and 18 had a dosage shortfall, leaving only 4/32 scenarios when the packaging size matched exactly the recommended dosage guidelines.

This is certainly an area where pharma packaging can help by ensuring labelling information corresponds accurately to the latest guidelines. Labelling guidelines also must keep up with wider health trends, such as the continued rise in child and adult obesity, which render recommended dosages outdated very quickly.

See also

Developments in digital packaging technologies are also helping pharmacists and doctors on the frontline monitor usage data and get a clearer picture of compliance trends. “Smart” blister packs are becoming more advanced, utilising built-in microchips to capture use-related data and remind patients when the next dose is due. The data collected from these packs can then be accessed by health professionals to give a clear picture of a patient’s medicine-taking behaviour at home.

Over the next five years, the integration of more advanced digital features into the packaging and delivery systems of antibiotics will become the norm.

Tackling pharmaceutical wastage

According to the UN, the release of antibiotics into the environment is accelerating bacterial evolution and the emergence of more resistant strains.

While the aim of the pharmaceutical industry is to improve public health (while of course turning a profit), a failure to address the environmental impact of antibiotic pollution is undermining efforts. Only recently, The Bureau of Investigative Journalism reported none of the 18 big pharma companies polled would reveal how much antibiotic discharge is released from their factories.

As pharmaceutical waste includes degraded and contaminated products, pharma packaging can play an important role.

In the pharma industry, innovation has always been synonymous with new drug discovery and approval. However, while there’s no arguing about the importance of new antibiotic development in the fight against AMR, the next generation of packaging and delivery systems deserve the same attention.

With AMR placing increasingly complex demands on the supply chain, packaging and delivery components must be precision engineered to ensure antibiotics are delivered and administered to patients as intended. This involves the mass adoption of Quality by Design (QbD).

The underlying principle of QbD is that quality is built into a product from the outset rather than tested during manufacture. Knowledge-based design has a key role to play in establishing “the rulebook” about how a multitude of factors impact safety, efficacy and patient experience.

The pharmaceutical waste includes expired products, dispensed drugs that are unwanted or discontinued, and contaminated medications

Poor quality medicine

A sufficient dose of the right antibiotic medicine early on in an infection will kill susceptible strains and help suppress newly-mutated pathogens from spreading. However, if the medicine being relied upon is poor quality or falsified, the whole treatment process is undermined.

Currently, the sale of counterfeit pharmaceuticals is the world’s largest fraud market, worth more than $200bn per year. However, digital packaging solutions are offering greater supply chain visibility and making falsification harder.

Digital mass serialisation is becoming a popular solution to combat counterfeiting. This involves the generation of a random, pseudo code in a sequential manner by a technology provider entered into their or their customers’ database for later verification. The authentication process matches the unique code on a product to those stored in the database. If the code is present, the product is deemed to be genuine.

Origin has developed Smart-i PharmiTrack technology for the control of physical products in the supply chain and can be applied to any size of batch or even to a single unit measure. This technology can identify the security status and location of your product remotely, at any time, making attempt to seize or introduce falsified medicines into the supply chain much more difficult.

Looking forward

AMR is a complicated and multi-dimensional issue, requiring the collaboration of national governments, NGOs, scientific experts and the general population to solve.

While pharma packaging cannot claim to offer the solution to the AMR crisis, at this point, every stakeholder in the healthcare supply chain has a responsibility to play their part.

What is a terrifying threat may also be an opportunity to drive “health for all” across the world, balancing the many economic, social and health inequalities which continue to exist today.

Credit: Origin

Share article

Jun 22, 2021

Bachem turns 50 - a timeline

3 min
As Bachem turns 50, we take a look at the company's history

Bachem, a supplier to pharmaceutical and biotechnology companies worldwide, is celebrating its 50th anniversary this month. We take a look at the Swiss company's history.  

1971 - beginnings

Bachem is founded by entrepreneur Peter Grogg in Liestal, a small town near Basel in Switzerland. Grogg started the firm with just two employees, and with a focus on peptide synthesis - peptides are composed of amino acids that have a variety of functions treating health conditions such as cancer and diabetes. 

1977 - 1981 - early growth

Bachem moves its headquarters to the Swiss town of Bubendorf, with eight employees. In 1978 the company produces peptides for use in medicines for the first time. In 1981 production capacity triples and the workforce grows to 150. 

 1987 - 1996 - worldwide expansion

The company expands into the US with Bachem Bioscience, Inc. in Philadelphia. To strengthen its presence in Europe, Bachem opens sales and marketing centres in Germany in 1988. 

Further sales centres open in France in 1993. By 1995 the company employs 190 people. In 1996 it acquires the second largest manufacturer of peptides in the world and forms Bachem California with a site in Torrance. 

 1998 - 2003 - Bachem goes public

Bachem company goes public and lists shares on the Swiss Stock Exchange. Further acquisitions include Peninsula Laboratories, Inc, based in California, and  Sochinaz SA, a Swiss-based manufacturer of active pharmaceutical ingredients.  By 2001, the company has 500 employees and sales reach 141 million CHF.

In 2003 the organisation is given a new legal holding structure to support its continued growth, which remains in place to this day. 

2007 - 2013 - acquisitions

Bachem acquires a brand by Merck Biosciences for ready-to-use clinical trial materials and related services. 

In 2013, together with GlyTech, Inc. Bachem announces the development of a new amino acid that can help to treat multiple sclerosis, with a world market of more than $4 billion. 

In 2015 it acquires the American Peptide Company (APC), which becomes integrated into Bachem Americas. 

2016 - 2019 - a global leader

In 2016 the group opens a new building dedicated to R&D projects and small series production in Bubendorf. With a total of 1,022 employees, the workforce exceeds the 1,000 mark for the first time in the company’s history. Sales are over the 200 million mark for the first time at 236.5 million CHF.
Bachem expands into Asia with the establishment of a new company in Tokyo called Bachem Japan K.K. 

By 2019 Bachem has a growing oligonucleotide portfolio - these are DNA molecules used in genetic testing, research, and forensics. It is hoped this will become a significant product range in the future. 

2020 - COVID-19

Despite the COVID-19 pandemic, Bachem secures its supply of active ingredients, and even increases it in critical areas. Sales exceed the 400 million Swiss franc mark for the first time, and  272 new employees are hired.  

2021 - a milestone anniversary

Bachem celebrates its 50th anniversary and position as a global leader in the manufacture of peptides. While it  remains headquartered in Bubendorf, the company employs 1,500 people at six locations worldwide. In the next five years there are  plans to continue expanding. 

Commemorating the company's anniversary, Kuno Sommer, Chairman of the Board of Directors, said: "Bachem's exceptional success story from a small laboratory to a global market leader is closely linked to Peter Grogg's values, and has been shaped by innovation, consistent quality and cost awareness, as well as by entrepreneurial vision."

Share article